Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 433

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 433
---
 the FDA.                                                        |

| 6. | Each outstanding Company                                                                                                          
 option was converted into an option to purchase a number of shares of Class A common stock, equal to the Company’s common shares  
 underlying the option multiplied by the Exchange Ratio, at an exercise price per share equal to the Company option exercise price 
 divided by the Exchange Ratio.                                                                                                    |

| 7. | Each warrant to purchase                                                                                                              
 the Company’s convertible preferred stock was converted into a warrant to acquire a number of shares of Class A common stock          
 obtained by dividing the warrant as-if-exercised liquidation preference by $10.00, with the exercise price equal to the total Company 
 warrant exercise amount divided by the number of shares of Class A common stock issuable upon exercise.                               |

| 8. | The Company’s convertible                                                                                                        
 notes automatically converted into shares of New CERo Series A Preferred Stock, at a conversion price equal to $1,000 per share. |

PIPE Financing

In February 2024, New CERo consummated a private
placement of 10,039 shares of New CERo Series A Preferred Stock, par value $0.0001 per share (the “New CERo Series A Preferred
Stock”), warrants to purchase 612,746 shares of common stock (the “Common Warrants”) and warrants to purchase 2,500
shares of Series A Preferred Stock (the “Preferred Warrants” and, together with the Common Warrants, the “PIPE Warrants”),
pursuant to the Amended and Restated Securities Purchase Agreement, dated February 14, 2024, by and among the Company, PBAX and certain
accredited investors (the “Initial Investors”) for aggregate cash proceeds to New CERo of approximately $10.0 million. On
April 1, 2024, we consummated a private placement of 626 shares of Series B Preferred Stock, pursuant to the Securities Purchase Agreement,
dated March 28, 2024, by and among us and certain accredited investors (the “Additional Investors” and, together with the
Initial Investors, the “PIPE Investors”), for aggregate cash proceeds to us of approximately $0.5 million. Such private placement
is expected to close on or around April 1, 2024. A portion of such Series A Preferred Stock was issued as consideration for the cancellation
of outstanding indebtedness or securities of the Company, including a promissory note of PBAX